Hong Kong · Delayed Price · Currency is HKD InnoCare Pharma Statistics
Total Valuation
InnoCare Pharma has a market cap or net worth of HKD 25.65 billion. The enterprise value is 20.55 billion.
| Market Cap | 25.65B |
| Enterprise Value | 20.55B |
Important Dates
The last earnings date was Monday, October 26, 2026.
| Earnings Date | Oct 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoCare Pharma has 1.70 billion shares outstanding. The number of shares has increased by 10.27% in one year.
| Current Share Class | 1.43B |
| Shares Outstanding | 1.70B |
| Shares Change (YoY) | +10.27% |
| Shares Change (QoQ) | -5.61% |
| Owned by Insiders (%) | 19.89% |
| Owned by Institutions (%) | 34.42% |
| Float | 1.15B |
Valuation Ratios
The trailing PE ratio is 13.43 and the forward PE ratio is 40.91.
| PE Ratio | 13.43 |
| Forward PE | 40.91 |
| PS Ratio | 6.57 |
| PB Ratio | 2.69 |
| P/TBV Ratio | 2.77 |
| P/FCF Ratio | 86.28 |
| P/OCF Ratio | 56.85 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.50, with an EV/FCF ratio of 69.25.
| EV / Earnings | 12.99 |
| EV / Sales | 5.27 |
| EV / EBITDA | 13.50 |
| EV / EBIT | 14.80 |
| EV / FCF | 69.25 |
Financial Position
The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.26.
| Current Ratio | 4.16 |
| Quick Ratio | 3.28 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 1.62 |
| Debt / FCF | 8.33 |
| Interest Coverage | 21.26 |
Financial Efficiency
Return on equity (ROE) is 18.34% and return on invested capital (ROIC) is 40.29%.
| Return on Equity (ROE) | 18.34% |
| Return on Assets (ROA) | 7.12% |
| Return on Invested Capital (ROIC) | 40.29% |
| Return on Capital Employed (ROCE) | 12.86% |
| Weighted Average Cost of Capital (WACC) | 6.37% |
| Revenue Per Employee | 2.83M |
| Profits Per Employee | 1.15M |
| Employee Count | 1,388 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 1.43 |
Taxes
In the past 12 months, InnoCare Pharma has paid 17.89 million in taxes.
| Income Tax | 17.89M |
| Effective Tax Rate | 1.11% |
Stock Price Statistics
The stock price has decreased by -14.07% in the last 52 weeks. The beta is 0.45, so InnoCare Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -14.07% |
| 50-Day Moving Average | 13.38 |
| 200-Day Moving Average | 13.04 |
| Relative Strength Index (RSI) | 45.29 |
| Average Volume (20 Days) | 6,280,225 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCare Pharma had revenue of HKD 3.93 billion and earned 1.59 billion in profits. Earnings per share was 0.90.
| Revenue | 3.93B |
| Gross Profit | 3.64B |
| Operating Income | 1.40B |
| Pretax Income | 1.61B |
| Net Income | 1.59B |
| EBITDA | 1.50B |
| EBIT | 1.40B |
| Earnings Per Share (EPS) | 0.90 |
Balance Sheet
The company has 7.59 billion in cash and 2.49 billion in debt, with a net cash position of 5.10 billion or 3.00 per share.
| Cash & Cash Equivalents | 7.59B |
| Total Debt | 2.49B |
| Net Cash | 5.10B |
| Net Cash Per Share | 3.00 |
| Equity (Book Value) | 9.60B |
| Book Value Per Share | 6.29 |
| Working Capital | 8.04B |
Cash Flow
In the last 12 months, operating cash flow was 453.72 million and capital expenditures -154.75 million, giving a free cash flow of 298.97 million.
| Operating Cash Flow | 453.72M |
| Capital Expenditures | -154.75M |
| Depreciation & Amortization | 99.66M |
| Net Borrowing | 509.21M |
| Free Cash Flow | 298.97M |
| FCF Per Share | 0.18 |
Margins
Gross margin is 92.52%, with operating and profit margins of 35.60% and 40.57%.
| Gross Margin | 92.52% |
| Operating Margin | 35.60% |
| Pretax Margin | 41.08% |
| Profit Margin | 40.57% |
| EBITDA Margin | 38.13% |
| EBIT Margin | 35.60% |
| FCF Margin | 7.57% |
Dividends & Yields
InnoCare Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 2.69% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.27% |
| Shareholder Yield | -10.27% |
| Earnings Yield | 7.44% |
| FCF Yield | 1.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for InnoCare Pharma is 18.27, which is 51.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 18.27 |
| Price Target Difference | 51.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 17.33% |
| EPS Growth Forecast (3Y) | 3.71% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoCare Pharma has an Altman Z-Score of 5.22 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.22 |
| Piotroski F-Score | 6 |